CHD4
History
%%{init: { 'logLevel': 'debug', 'theme': 'dark' } }%%
timeline
title Publication timing
2022-07-06 : Burkhardt : BL
## Relevance
tier by entity
| Entity | Tier | Description |
|---|---|---|
 |
2 | relevance in BL not firmly established |
Mutation incidence in large patient cohorts (GAMBL reanalysis)
| Entity | source | frequency (%) |
|---|---|---|
| BL | GAMBL genomes+capture | 3.93 |
| BL | Thomas cohort | NA |
| BL | Panea cohort | NA |
Mutation pattern and selective pressure estimates
| Entity | aSHM | Significant selection | dN/dS (missense) | dN/dS (nonsense) |
|---|---|---|---|---|
| BL | No | No | 1.781 | 0 |
| DLBCL | No | No | 3.513 | 0 |
| FL | No | No | 1.815 | 0 |
[!NOTE] First described in BL in 2022 by Burkhardt B
View coding variants in ProteinPaint hg19 or hg38
View all variants in GenomePaint hg19 or hg38
## CHD4
Expression 
## References 1.
Burkhardt B, Michgehl U, Rohde J, Erdmann T, Berning P, Reutter K, Rohde
M, Borkhardt A, Burmeister T, Dave S, Tzankov A, Dugas M, Sandmann S,
Fend F, Finger J, Mueller S, Gökbuget N, Haferlach T, Kern W, Hartmann
W, Klapper W, Oschlies I, Richter J, Kontny U, Lutz M, Maecker-Kolhoff
B, Ott G, Rosenwald A, Siebert R, von Stackelberg A, Strahm B, Woessmann
W, Zimmermann M, Zapukhlyak M, Grau M, Lenz G. Clinical relevance of
molecular characteristics in Burkitt lymphoma differs according to age.
Nat Commun. 2022 Jul 6;13(1):3881. PMCID: PMC9259584
